The DLX1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HAP1 cell line, designed to disrupt the expression of the DLX1 gene. This product provides a heterogeneous pool of edited cells, facilitating robust loss-of-function studies without the clonal selection step. The knockout model enables investigation of DLX1-dependent cellular phenotypes and transcriptional networks in a defined genetic background.
HAP1 cells are a near-haploid human cell line originally derived from the KBM-7 chronic myeloid leukemia (CML) line, which was isolated from a patient in blast crisis. These cells are BCR-ABL1 positive and have been adapted to adherent growth, offering a genetically simplified platform for functional genomics. Their haploid nature reduces gene redundancy, making them particularly suitable for CRISPR-based knockout experiments and phenotypic screens.
DLX1 encodes a homeobox transcription factor that plays a critical role in embryonic development, neurogenesis, and craniofacial patterning. It functions downstream of the Sonic Hedgehog (SHH) signaling pathway, where SHH binding to PTCH1 relieves SMO inhibition, leading to GLI transcription factor activation and subsequent DLX1 expression. DLX1, often in concert with its paralog DLX2 and interacting cofactors such as MSX1, MSX2, and p300/CBP, directly regulates genes essential for GABAergic interneuron differentiation, including GAD1, GAD2, LHX6, and ARX. Additional upstream regulators like FGF8, BMP4, and FOXG1 further modulate DLX1 activity, integrating signals from multiple morphogen pathways.
In the HAP1 CML background, DLX1 knockout uncouples its neurodevelopmental functions from the neuronal context, allowing researchers to examine its role in proliferation, apoptosis, and transcriptional regulation within a cancer cell model. The BCR-ABL1 oncogenic driver may interact with DLX1-mediated transcriptional networks, offering a unique system to explore potential crosstalk between developmental transcription factors and leukemogenic signaling. This polyclonal population is well-suited for high-throughput screening and validation experiments, leveraging HAP1??s genetic tractability.
Typical applications include western blotting and RT-qPCR to confirm DLX1 ablation, Sanger sequencing to verify CRISPR-induced mutations, immunofluorescence to assess protein localization, RNA-seq for transcriptome-wide impact, and functional assays such as MTT and BrdU incorporation for proliferation, or Annexin V staining for apoptosis. This product supports investigations into neurodevelopmental gene function in a non-neuronal environment, as well as basic studies on SHH signaling and GABAergic gene regulation. For further technical details or custom requests, please contact Ascent Research.
